Viridian Therapeutics, Inc.\DE (VRDN) Interest Coverage Ratio Growth (3y) (2016 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) Interest Coverage Ratio Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 40.09% |
| 10 | Viridian Therapeutics, Inc.\DE | 653.63 Mn | 653.63 Mn | - | 54.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.76% |
| Dec 31, 2025 | -26.39% |
| Sep 30, 2025 | 21.71% |
| Jun 30, 2025 | 46.52% |
| Dec 31, 2024 | -62.58% |
| Mar 31, 2024 | -3.54% |
| Dec 31, 2023 | 41.40% |
| Sep 30, 2023 | -99.08% |
| Jun 30, 2023 | -222.73% |
| Mar 31, 2023 | -216.53% |
| Sep 30, 2022 | -45.87% |
| Jun 30, 2022 | -48.81% |
| Dec 31, 2021 | -22.14% |
| Mar 31, 2021 | -43.36% |
| Dec 31, 2020 | -260.09% |
| Sep 30, 2020 | 20.16% |
| Jun 30, 2020 | 16.42% |
| Mar 31, 2020 | 12.71% |
| Sep 30, 2019 | 2.85% |
| Jun 30, 2019 | -2.57% |